Novartis Cosentyx gets positive CHMP opinion for expanded use in childhood arthritic conditions
Basel: Novartis has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab), used alone or...